Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121266 | 0.74 | GRIN1 (0.42) | — | |
| SCHEMBL23851432 | 0.70 | NFE2L2 (0.33) | TRIM24TRIM33 | |
| SCHEMBL1255555 | 0.67 | GRIN1 (0.47) | — | |
| SCHEMBL24608783 | 0.67 | GRIN1 (0.44) | — | |
| SCHEMBL1255604 | 0.66 | GRIN1 (0.50) | — | |
| SCHEMBL28635906 | 0.66 | KDM4E (0.32) | — | |
| SCHEMBL20558313 | 0.65 | CYP19A1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL2392462 | 0.65 | HSP90AA1 (0.35) | — | |
| Hydrochloric Acid SCHEMBL667557 | 0.65 | HSP90AA1 (0.35) | — | |
| SCHEMBL31114034 | 0.64 | VNN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020085234-A1 | MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2020-04-30 | — | — | WO | disclosed |
| EP-2834238-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9296745-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2834238-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | Pfizer Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150416-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087585-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, PLAAT2 | TRIM24 4029/4885TRIM33 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.